935106861
info@markelab.com
Precio
Precio a consultar
BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.
Primary Antibodies
polyclonal
human,mouse,rat
breast cancer anti-estrogen resistance 1
Rabbit
IgG
Unconjugated
liquid
ELISA, WB
93-120 kDa
≥95% as determined by SDS-PAGE
Immunogen affinity purified
WB : 1:500-1:2000
100µg
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
BCAR1
BCAR1, CAS, CAS1, CASS1, CRKAS, P130Cas, Cas family scaffolding protein, Cas family scaffold protein, BCAR1 scaffold protein, Cas family member
This product is for research use only.
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más